Home Posts tagged Novo Nordisk

Novo Nordisk

NEWS DESK

Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes

Novo Nordisk today announced positive topline results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type 2 diabetes in children and adolescents aged 10–17 years with type 2 diabetes. Oral semaglutide demonstrated a superior reduction in HbA1c (a measure of blood sugar control) over placebo in the trial and showed a well-tolerated […]
NEWS DESK

Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25 mg was associated with significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison. It is important to note that the FDA recently approved orforglipron
NEWS DESK

Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes. The approval offers the only once‑weekly […]
NEWS DESK

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner’s National Priority Voucher for Wegovy® HD, accelerating its review and underscoring its potential to address critical patient
NEWS DESK

NOVO NORDISK HOSTS IDOL SUMMIT TO RETHINK WEIGHT-MANAGEMENT COMMUNICATION TOGETHER WITH DIGITAL AND KEY OPINION LEADERS

Novo Nordisk successfully concluded the iDOL Summit: Reimagining Weight Management with Digital Opinion Leaders, held between 27–28 January in Dubai. As the first summit of its kind initiated by a pharmaceutical company in the Middle East and Africa, the event brought together digital opinion leaders, healthcare professionals, media representatives, digital creators and
NEWS DESK

Connected Health and Novo Nordisk join forces to tackle obesity in the UAE with brand-new, patient-first digital model

Novo Nordisk, the global healthcare company seeking to drive change to defeat serious chronic diseases, and Connected Health, the Emirati digital health company making healthcare more personal, today announced a partnership set to transform the patient experience for the one in three people in the United Arab Emirates living with obesity or overweight. The collaboration
NEWS DESK

Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring

Novo Nordisk presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver Meeting® 2025, in Washington, D.C., evaluating the effects of semaglutide 2.4 mg in people with metabolic dysfunction-associated steatohepatitis (MASH) and moderate- to-advanced liver scarring (fibrosis). Results from a post hoc analysis of the
NEWS DESK

People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being

PR News Desk
Novo Nordisk today announced results from the US-based INFORM survey of people taking semaglutide for weight management (Wegovy®), at the European Association for the Study of Diabetes (EASD) 2025, Vienna, Austria. The INFORM survey revealed that individuals experienced a substantial drop in food noise after starting Wegovy® treatment, alongside notable improvements in
NEWS DESK

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

PR News Desk
Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy® (semaglutide 2.4 mg) compared with tirzepatide treatment in people with overweight
NEWS DESK

Novo Nordisk announced the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions

PR News Desk
Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, semaglutide 7.2 mg, the higher dose of Wegovy® demonstrated a mean weight loss of 21% with a third of participants […]